NurExone Exosomes to Be Used in Cutting-Edge Molecular Research at Hebrew University’s Burstyn-Cohen Lab

On July 19, 2022, NurExone Biologic Inc. (TSXV: NRX) (formerly, EnerSpar Corp.), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal injuries and other central nervous system ("CNS") indications, announced the signing of a Material Transfer Agreement dated July 18th, 2022 with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. ("Yissum"), the wholly-owned subsidiary and technology transfer company of the Hebrew University of Jerusalem. The Agreement relates to the transfer of certain biological, chemical, and other tangible materials (the "Materials") to Yissum for use by Professor Tal Burstyn-Cohen, PhD, and her team at the Hebrew University. Professor Burstyn-Cohen is an experienced researcher at the Hebrew University and leader of the Burstyn-Cohen Lab which researches molecular and cellular mechanisms that underlie tissue homeostasis in health.

Login Or Register To Read Full Story